OCT 2 2 2012

Column E Explanation

This form is intended as an aid to completing the Column E explanation. It is not an official form and its use is voluntary. Names, addresses, protocols, veterinary care programs, and the like, are not required as part of an explanation. A Column E explanation must be written so as to be understood by lay persons as well as scientists.

1. Registration Number: 41-R-0074

2. Number 23 of animals used in this study.

3. Species (common name) Rabbit of animals used in the study.

4. Explain the procedure producing pain and/or distress.
Intracutaneous Reactivity test - 0.2 ml of the test or control solution is injected intracutaneously at 5 sites on one side of the rabbit. Similarly 0.2 ml of the control will be injected at 5 sites on the contralateral side of the rabbit. Repeat steps above with the polar solvent injected more dorsal than the non polar solvent. Observations are performed on each injection site immediately after injection and at 24, 48 and 72 hours after injection. Tissue reactions are graded for erythema and edema for each injection site at each time interval.

5. Provide scientific justification why pain and/or distress could not be relieved. State methods or means used to determine that pain and/or distress relief would interfere with test results. (For Federally mandated testing, see Item 6 below)
Study is designed to test the allergenic potential of medical devices. The use of anesthetics, analgesics, or tranquilizers to alleviate pain is prohibited due to the potential molecular interaction between the drugs and compounds associated with the medical device. This interaction may cause a response (inhibitory or synergistic) that could affect the outcome of the study. In order to effectively evaluate the characteristics of the devise the use of medications is prohibited.

6. What, if any, federal regulations require this procedure? Cite the agency, the code of Federal Regulations (CFR) title number and the specific section number (e.g., APHIS, 9 CFR 113.102):

Agency _____ CFR _____

ISO 10993-10

OCT 2 2 2012

Column E Explanation

This form is intended as an aid to completing the Column E explanation. It is not an official form and its use is voluntary. Names, addresses, protocols, veterinary care programs, and the like, are not required as part of an explanation. A Column E explanation must be written so as to be understood by lay persons as well as scientists.

1. Registration Number: 41-R-0074

2. Number 23 of animals used in this study.

3. Species (common name) Rabbit of animals used in the study.

4. Explain the procedure producing pain and/or distress.

Animal irritation test - Test device patch and control patch applied directly to skin. Application site wrapped with bandage for minimum of 4 hours. at the end of contact duration bandage is removed and sites where positive control and control patches were located are marked with permanent ink. Observations are performed on each application site 1 hour, 24, 48 and 72 hours after unwrap. Tissue reactions are graded for erythema and edema for each application site at each time interval.

5. Provide scientific justification why pain and/or distress could not be relieved. State methods or means used to determine that pain and/or distress relief would interfere with test results. (For Federally mandated testing, see Item 6 below)

Study is designed to test the allergenic potential of medical devices. The use of anesthetics, analgesics or tranquilizers to alleviate pain is prohibited due to the potential molecular interaction between the drugs and the compounds associated with the medical device. This interaction may cause a response (inhibitory or synergistic) that could affect the Outcome of the Study. In order to effectively evaluate the characteristics of the device, the use of medications is prohibited

6. What, if any, federal regulations require this procedure? Cite the agency, the code of Federal Regulations (CFR) title number and the specific section number (e.g., APHIS, 9 CFR 113.102):

Agency _____ CFR _____

ISO 10993-10

OCT 22 2012

Column E Explanation

This form is intended as an aid to completing the Column E explanation. It is not an official form and its use is voluntary. Names, addresses, protocols, veterinary care programs, and the like, are not required as part of an explanation. A Column E explanation must be written so as to be understood by lay persons as well as scientists.

1. Registration Number: 41-R-0074

2. Number 100 of animals used in this study.

3. Species (common name) Guinea Pig of animals used in the study.

4. Explain the procedure producing pain and/or distress.

(b) (6), (b) (7)(C)

Study has one induction and one challenge phase.
Induction phase - administer the test sample by topical application to the clipped left upper back of each test animal using patches soaked in the test sample. bandaging and patches are removed after 6 hours. Procedure is performed 3days per week for 3 weeks. Control animals are tested in the same manner using appropriate control.
Challenge Phase - 14days after last induction application all test and control animals are challenged with test sample. Test sample is administered by a single topical application to the clipped right upper back of each animal using patches soaked in test sample. bandages and patches are removed after 6 hours. At 24 hours after primary challenge the animals hair is removed. 2 hours after hair removal test sites are graded for erythema and edema. grading is repeated 48 hours after challenge removal.

5. Provide scientific justification why pain and/or distress could not be relieved. State methods or means used to determine that pain and/or distress relief would interfere with test results. (For Federally mandated testing, see Item 6 below)
Study is designed to test the allergenic potential of medical devices. The use of anesthetics, analgesics, or tranquilizers to alleviate pain is prohibited due to the potential molecular interaction between the drugs and the compounds associated with the medical device. this interaction may cause a response (inhibitory or synergistic) that could affect the outcome of the study. In order to effectively evaluate the characteristics of the device the use of medications is prohibited.

6. What, if any, federal regulations require this procedure? Cite the agency, the code of Federal Regulations (CFR) title number and the specific section number (e.g., APHIS, 9 CFR 113.102):

Agency _____ CFR _____

ISO 10993-10

OCT 22 2012

Column E Explanation

This form is intended as an aid to completing the Column E explanation. It is not an official form and its use is voluntary. Names, addresses, protocols, veterinary care programs, and the like, are not required as part of an explanation. A Column E explanation must be written so as to be understood by lay persons as well as scientists.

1. Registration Number: 41-R-0074

2. Number 102 of animals used in this study.

3. Species (common name) Guinea Pig of animals used in the study.

4. Explain the procedure producing pain and/or distress.

Guinea Pig Maximization Test - Study is comprised of 2 induction phases (intradermal and topical) and 1 challenge phase. Intradermal induction uses a series of intradermal injections (0.1ml) in combination with freunds complete adjuvant and the test extract to enhance the state of immunological activity of the animal to the material of interest. a pretreatment of 10% sodium laaryl sulfate is massaged into the skin prior to the start of the topical induction. Topical induction involves application of a patch containing the test sample to the intrascapular region of the animal. After induction phased animals will observed for 14 days then all control and test animals will be challenged with the control and test sample. Observe the appearance of the challenge skin sites for evidence of skin sensitization at 24 and 48 hours after challenge.

5. Provide scientific justification why pain and/or distress could not be relieved. State methods or means used to determine that pain and/or distress relief would interfere with test results. (For Federally mandated testing, see Item 6 below)

Study is designed to test the allergenic potential of medical devices. The use of anesthetics, analgesics, or tranquilizers to alleviate pain is prohibited due to the potential molecular interaction between the drugs and the compounds associated with the medical device. this interaction may cause a response (inhibitory or synergistic) that could affect the outcome of the study. in order to effectively evaluate the characteristics of the device the use of medications is prohibited.

6. What, if any, federal regulations require this procedure? Cite the agency, the code of Federal Regulations (CFR) title number and the specific section number (e.g., APHIS, 9 CFR 113.102):

Agency _____ CFR _____

ISO 10993-10